拉丁美洲多发性硬化症患者中新冠病毒疫苗短期安全性评估。
Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America.
作者信息
Alonso Ricardo, Chertcoff Aníbal, Leguizamón Felisa Del V, Galleguillos Goiry Lorna, Eizaguirre Maria B, Rodríguez Roberto, Sosa Marta, Carballido Susana, Cruchet Verónica, de Jong-Martis Agnes, Giachello Susana, Henestroza Paula, Ferrandina Flavia, Bauer Johana, Carrá Adriana, Silva Berenice A
机构信息
Centro Universitario de Esclerosis Múltiple - CUEM, Hospital Ramos Mejía, Buenos Aires, Argentina.
Esclerosis Múltiple Argentina - EMA, Buenos Aires, Argentina.
出版信息
Mult Scler J Exp Transl Clin. 2021 Nov 29;7(4):20552173211061543. doi: 10.1177/20552173211061543. eCollection 2021 Oct.
BACKGROUND
To date, there are no data available on the safety of COVID-19 vaccines in Latin American patients with Multiple Sclerosis (MS).
OBJECTIVE
Characterize safety of COVID-19 vaccines in Latin American (LATAM) patients with Multiple Sclerosis (pwMS).
METHODS
A cross-sectional study between February 1, 2021, and April 30, 2021. Individuals with MS from LATAM countries were invited to participate in a self-administered web-based survey, through MS patient organizations from the region.
RESULTS
393 vaccinated pwMS from 10 different Latin American countries were included. The vaccines administered were: inactivated virus vaccines (IVV) in 38.2% of patients, adenovirus vector vaccines (AdV) in 48.8% and mRNA vaccines 13%. All patients received at least one dose of any of the COVID-19 vaccines and 123 (31.3%) declared receiving a second dose. Mean (SD) age 41.5 (11.8) years, 82.4% female, MS disease duration: 8.4 (8.2) years. No serious adverse events were reported with any of the COVID-19 vaccines after either the first or second dose. A lower frequency of adverse events was found with IVV (22%) in comparison with AdV (46.4%) and mRNA (35.3%) ( < 0.01). Five participants reported having an MS relapse after IVV first dose.
CONCLUSION
COVID-19 vaccines applied in LATAM proved safe for MS patients.
背景
迄今为止，尚无关于新冠病毒疫苗在拉丁美洲多发性硬化症（MS）患者中安全性的数据。
目的
描述新冠病毒疫苗在拉丁美洲多发性硬化症（pwMS）患者中的安全性。
方法
一项于2021年2月1日至2021年4月30日开展的横断面研究。通过该地区的MS患者组织，邀请来自拉丁美洲国家的MS患者参与一项基于网络的自我管理调查。
结果
纳入了来自10个不同拉丁美洲国家的393名接种疫苗的pwMS患者。所接种的疫苗为：38.2%的患者接种了灭活病毒疫苗（IVV），48.8%接种了腺病毒载体疫苗（AdV），13%接种了mRNA疫苗。所有患者均接受了至少一剂任何一种新冠病毒疫苗，123名（31.3%）宣称接种了第二剂。平均（标准差）年龄为41.5（11.8）岁，女性占82.4%，MS病程为8.4（8.2）年。在接种第一剂或第二剂任何一种新冠病毒疫苗后，均未报告严重不良事件。与AdV（46.4%）和mRNA（35.3%）相比，IVV的不良事件发生率较低（22%）（<0.01）。5名参与者报告在接种IVV第一剂后出现MS复发。
结论
在拉丁美洲应用的新冠病毒疫苗对MS患者而言是安全的。
Zotero 插件